Real-world data on the new anti-sclerostin antibody drug, romosozumab, remain scarce.
There is a strong need to accumulate and analyze data on romosozumab treatment for such …

Context Globally, one in five men aged> 50 years is predicted to experience an osteoporotic
fracture. Because of the treatment gap in osteoporosis and the paucity of bone-forming …

This is a comment on" Romosozumab in postmenopausal women with osteopenia." N Engl J
Med. 2014 Apr 24; 370 (17): 1664. This is a comment on" Romosozumab in …

ABSTRACT In the pivotal Fracture Study in Postmenopausal Women with Osteoporosis
(FRAME; NCT01575834), 1 year of the bone‐forming agent romosozumab significantly …

Osteoporosis is a chronic skeletal disease with an increasing prevalence. Romosozumab,
as a monoclonal anti-sclerostin antibody with a dual function, has been produced. In this …

Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The
monoclonal antibody romosozumab binds to sclerostin and increases bone formation …

Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In
this study of postmenopausal women with low BMD, a second course of romosozumab …

Abstract Purpose of Review Authors review the safety and efficacy of romosozumab for the
treatment of osteoporosis as demonstrated in three phase III clinical trials and offer insights …

Background Romosozumab, a monoclonal antibody that binds sclerostin, increases bone
formation and decreases bone resorption. Methods We enrolled 7180 postmenopausal …

Increased understanding of the Wnt signaling pathway has led to the development of
romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis …